Evaluation of anti-tumor activity of borated camptothecin derivatives targeting topoisomerase 1 against hepatocellular carcinoma and intrahepatic cholangiocarcinoma
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2025.109186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Mi Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: DNA Topoisomerases, Type I, Cholangiocarcinoma, Carcinoma, Hepatocellular, Topoisomerase I Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Program of Guizhou Province.
Abstract (Originalsprache)
OBJECTIVES: Primary liver cancer, including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), is a common malignancy lacking effective chemotherapies. Camptothecin (CPT) derivatives, though approved for treatment, face limitations due to systemic toxicity. Boration has been shown to improve drug bioavailability and reduce toxicity. We designed and synthesized a new 9-borate CPT derivative, CPT-01, to evaluate its anti-tumor potential. METHODS: In vitro assays, including EdU incorporation, colony formation, and flow cytometry, assessed CPT-01's effects on proliferation, apoptosis, and cell cycle. AKT/Ras- and AKT/NICD-induced primary mouse models of HCC and ICC were used for in vivo evaluation. Molecular mechanisms were explored using western blotting, immunohistochemistry, topoisomerase I inhibition assays, and molecular docking. RESULTS: CPT-01 exhibited stronger anti-tumor activity than topotecan (TPT) in both cancer cell lines and mouse models. In vivo, it showed greater efficacy in AKT/Ras-induced HCC and AKT/NICD-induced ICC models, with no significant toxicity at therapeutic doses. Mechanistically, CPT-01 inhibited topoisomerase I, inducing DNA damage, cell cycle arrest, and apoptosis. CONCLUSIONS: CPT-01 demonstrates enhanced anti-tumor efficacy and reduced toxicity compared to TPT, offering promising clinical potential for liver cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; School of Pharmacy, Lanzhou University, Lanzhou 730000, China.
- School of Pharmacy, Lanzhou University, Lanzhou 730000, China. Electronic address: yqliu@lzu.edu.cn.
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, 430030. Electronic address: doctoryf@126.com.
Förderung
- National Natural Science Foundation of China
- Science and Technology Program of Guizhou Province
Zitieren
APA
Zhang, M., Xiang, Y., Li, C., Xu, C., Chen, G., Long, R., Chen, C., Liu, Y., & Ye, F. (2025). Evaluation of anti-tumor activity of borated camptothecin derivatives targeting topoisomerase 1 against hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.109186
Vancouver
Zhang M, Xiang Y, Li C, Xu C, Chen G, Long R, et al. Evaluation of anti-tumor activity of borated camptothecin derivatives targeting topoisomerase 1 against hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.109186
BibTeX
@article{Zhang2025,
author = {Zhang, Mi and Xiang, Yifei and Li, Chun and Xu, Chuanrui and Chen, Guisha and Long, Ruitao and Chen, Chanyuan and Liu, Yingqian and Ye, Feng},
title = {Evaluation of anti-tumor activity of borated camptothecin derivatives targeting topoisomerase 1 against hepatocellular carcinoma and intrahepatic cholangiocarcinoma},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2025.109186}
}
EUVIMED